visiongain
Print this page . Send to a friend . Bookmark this page
Login/Register  BasketBasket Checkout
  • pharma
  • pharmapharma

YOU MIGHT BE INTERESTED IN

  1. Neurodegenerative Disease Drug Market Analysis and Forecasts 2007

    Neurodegenerative Disease Drug Market Analysis and Forecasts 2007

    With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.

    ...more details
  2. Cannabinoid Market Forecasts & Analysis to 2012

    Cannabinoid Market Forecasts & Analysis to 2012

    With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.

    ...more details
  3. Parkinson's Disease: Market analysis and forecasts, 2008-2012, 2017 & 2022

    Parkinson's Disease: Market analysis and forecasts, 2008-2012, 2017 & 2022

    Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.

    ...more details
  4. Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy

    Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy

    Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities.

    ...more details
  5. Blockbuster Drugs - Create, Develop and Market a Billion Dollar Drug 2007-2012

    Blockbuster Drugs - Create, Develop and Market a Billion Dollar Drug 2007-2012

    This unique in-depth management report examines the future prospects for blockbuster drugs from 2007-2012. It delivers direct to you future sales forecasts for leading pharmaceutical blockbuster products. In 2006, there were over a hundred of those high revenue generating drugs in the global market. This detailed report also highlights pipeline developments, potential blockbusters on the market and important contemporary issues, especially commercial drivers and restraints.

    ...more details
  6. In Vitro Diagnostics Market Report & Analysis 2008-2023

    In Vitro Diagnostics Market Report & Analysis 2008-2023

    Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics - especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers.

    ...more details

REPORT

rss_Pharma.jpg...see all
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022

Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022

Download reportDownload sample
  • Publication date: 15/10/2007
  • Number of Pages: 116
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped.

Over the past decade the AD market has been flagged by a quartet of approved pharmacological agents; acetyl cholinesterase inhibitors (AchEIs), N-methyl D-aspartate (NMDA) receptor antagonists and other non-AD specific therapeutics for management of comorbidities. The AchEIs comprise products from some of the leading larger pharmaceutical companies;

• Esia/Pfizer’s Aricept (Donepizel)
• Novartis Exelon (Rivagstigmine) and
• Shire/J&J’s Razadyne (galantamiune) previously Reminyl and recent entrant a non-AchEI
• NMDA receptor antagonist Mementine, marketed in the US by Forest as Nemanda and in EU as Ebixa by Lundbeck Mementine

However, all the listed drugs only elicited modest clinical benefits in treating the various stages of the AD. In addition, the UK National Institute of Clinical Excellence (NICE) decision not to place the drugs on the NHS for reimbursement generated major controversy across the larger markets, only to affect the potential revenue growth on the major drugs particularly in the UK, one of the significant markets.

What questions does the report answer?
• Which regions have the highest prevalence of AD diseases today and by 2050?
• Do you know the cost of AD across the larger markets?
• Who are the market leaders in this class of therapy?
• What market share was accounted for by the quartet of AD drugs in the major markets?
• Do you know the magnitude of the controversy generated by NICE’s, as it deems the major drugs not cost-effective on the NHS?
• Do you know how much the AD market will be worth by Q4 of 2007 and its potential value by 2012, 2017 and 2022?
• Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
• Do you know which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the AD pipelines that are deemed to answer unmet therapeutic needs in the future?

Revenues of the only approved AD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $3 billion in 2006, with revenues expected to exceed $5 billion by 2012. By 2014, Visiongain anticipates that, all the AD approved therapies will come of patents in the major markets signaling a potential genericisation of the AD market.

With looming patient potential over the major products, Visiongain’s market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the sector will see the penetration of highly innovative AD products presently in late-phase clinical studies into the AD arena, only heralded by modest therapies, as opposed to the large outcry for highly effective drugs complimented by value for money by inter-country healthcare regulatory authorities.

With country-by-country focus on the markets of:
- US
- UK
- Germany
- Japan
- France
- Italy
- Spain

This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the demand for a shift from modest therapies to highly efficacious drugs for the treatment of AD. Amongst the catalogue of products in the AD pipeline is the insurgence of the highly anticipated Anti Beta-Amyloid Therapies, a treatment against beta-amyloid plaque formation the hallmark of AD. This area of research including Biomarkers has generated a high level of interest from; top-tier companies, the major players in the AD circle and niche companies alike.

This visiongain report  is the single tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of drugs to improve the quality of live suffers of AD and their caregivers. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

When you buy this report, you will also get an understanding, through our overview; of how present changes in Governmental Pharmaceutical Policies with respect to cost-cutting coupled with re/no imbursement has had consequential impact on the AD market products in the 7MM. The Alzheimer’s Disease Market Analysis & Forecasts 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2007 MS report, you will be buying current and vital information on the vast array of compounds in pipeline that are marked for potential success in the long-term treatment of AD.

Table of Contents

Chapter 1. Executive Summary

Chapter 2. An Introduction to Alzheimer’s Disease
2.1  Introduction
2.2  Symptoms and Differential Diagnosis
2.3 The Risk Factors for AD
2.4  Type of Protein as a Cause for AD?
2.4.1 Neuronal and Synaptic Loss of AD
2.4.2  Chromosomal Mutations of AD
2.4.3  Inflammation of AD
2.4.4  Using brain scans to detect Alzheimer's
2.5  The Demographics for AD
2.6  Financial Burden of AD

Chapter 3. Pharmacotherapy for Alzheimer’s Disease
3.1  Current AD Pharmaceutical Drug Therapies
3.2  Acetylcholinesterase Drugs - How do you Treat Mild to Moderate AD?
3.2.1 Pfizer/Eisai Aricept (Donepezil hyrdochloride) - The leading drug choice for AD 
3.2.1 Aricept clinical data
3.2.1.1 Pre-clinical data
3.2.1.2 Aricept clinical data outcomes
3.2.1.3  Eisai and Pfizer Aricept post marketing research for AD
3.2.1.4  Eisai severe Alzheimer's disease trials
3.3  Novartis Excelon (Rivastigamine) - Popular Drug Therapy for AD
3.3.1 Excelon mild-to-moderately severe Alzheimer's disease clinical data
3.3.2  J&J/ Shire Razadyne (Galantamine) is a Mild-to-moderate Treatment for AD
3.3.3  J&J/ Shire Reminyl (Galantamine) clinical studies
3.3.4  Forest and Lundbeck (Namenda/Ebixa) The Drug Treatments for Moderate to Severe AD
3.3.4.1  Lundbeck Ebixa (Namenda) severe Alzheimer's disease clinical data
3.3.4.2  Lundbeck Ebixa (Namenda) mild-to-moderate Alzheimer's disease clinical data
3.3.5  Comparative efficacy of Clinical Approved AD drugs
3.3.6  Cognex (Tacrine)
3.3.7  Non steroidal anti-inflammatory drugs (NSAIDs)
3.4  Comorbid Conditions
3.5  Depression associated with Alzheimer's disease and its management

Chapter 4. UK Alzheimer's Disease treatment guidelines
4.1 UK-National Institute for Clinical Excellence guidelines
4.2  NICE 2001 AD guideline
4.2.1  NICE reversal to 2001 AD guidance
4.2.2  Stakeholders' reaction to NICE 2001 AD guidelines reversal
4.2.3  NICE 2006 AD Guidance Review- Aricept, Razadyne, Exelon and Memantine
4.2.4  Judicial Review of NICE guideline 2007

Chapter 5. Global AD market
5.1  Overview of Global AD market and Geographical analysis
5.2 US Alzheimer's disease market
5.3  US AD Market Drivers and Restraints
5.3.1 Market Drivers
5.3.2 Market Restraints
5.4  Japan Alzheimer's disease Market
5.5  Japan Market Drivers and Restraints
5.5.1  Market Drivers
5.5.2  Market Restraints
5.6  France Alzheimer's disease Market
5.7  France AD Market Drivers and Restraints
5.7.1 Market Drivers
5.7.2  Market Restraints
5.8  Germany Alzheimer's disease Market
5.9  Germany AD Market Drivers and Restraints
5.9.1  Market Drivers
5.9.2 Market Restraints
5.10  UK Alzheimer's disease Market
5.11  UK AD Market Drivers and Restraints 
5.11.1 Market Drivers
5.11.2  Market Restraints
5.12  Italy's Alzheimer's disease Market
5.13  Italy AD Market Drivers and Restraints
5.13.1  Market Drivers
5.13.2  Market Restraints
5.14  Spain's Alzheimer's disease Market
5.15  Spain AD Market Drivers and Restraints
5.15.1  Market Drivers
5.15.2  Market Restraints

Chapter 6. Key players in Alzheimer’s Disease Pharmacotherapy
6.1  Eisai/Pfizer's Aricept
6.1.1  Eisai Aricept product expansion
6.1.2  Eisai R&D
6.2  Forest Laboratories Namenda /Lundbeck
 Ebixa product expansion
6.3  Shire Razadyne product expansion
6.4  Novartis Exelon product expansion
6.4.1  Novartis Exelon TransdermalPatch for AD
6.4.2  Potential Success of Exelon Transdermal Patch
6.4.3  Novartis’ Exelon and Forest Namenda combinatorial study
6.5  Will there be generic competition?
6.6  Market growth indications

Chapter 7. Alzheimer’s disease  R&D and pipeline

7.1  Unmet medical needs for Alzheimer’s disease
7.2  Present clinical approaches to delivering AD therapies
7.2.1  Biomarkers a prospective diagnostic tool
7.3  Overview of pipeline products
7.3.1  Pipeline Drugs for AD
7.3.2  Neurochem's Alzhemed (anti-amyloid compound) illuminates strong therapeutic potential
7.3.3  Forest’s Neramexane potential follow-on product for Namenda
7.3.4.  Other compounds presently in the pipeline
7.3.4.1  PBT-1 (Coloquinol)
7.3.4.2  Phenserine
7.3.4.3  Allon Therapeutics'AL-108 and AL-208 to inhibit neuronal death
7.3.4.4  Martek's DHA reduces brain lesions in AD animal models
7.3.4.5  Phytopharm Cogane -an orally active neuroprotective compound
7.3.4.6  Nicotine Replacement Therapy as a Potential Treatment for AD
7.4  Emerging Therapies for Alzheimer's disease
7.4.1  Vitamin E (Antioxidants) for AD
7.4.2  Research has revealed that Vitamin E, Vitamin  C and other health foods possess oxidative properties.
7.4.3  OTC Ginko Biloba May Slow AD Symptoms
7.4.4  Oestrogen HRT May Protect Against AD

Chapter 8. Conclusions

8.1  Expansion of Global Population
8.2  Prevalence of Alzheimer’s disease in the Major Markets
8.3  FDA Approved Alzheimer’s disease Therapies and NICE’s Cost-Effective Analysis
8.4  Alzheimer’s disease Drug Sales across Major Markets 2006
8.5  Barriers to Generic entrants
8.6  Alzheimer’s disease Revenue ($m) Forecast
8.7  Leading Companies with Products in late-stage Alzheimer’s disease Pipeline

Table 1.1 Prevalence of AD  Accross The Seven Major Markets   (2006)
Table 1.2.  AD Revenue Forecast ($m) for Seven Major  Markets,2007-2012,2017 & 2022
Table 1.3  SWOT Analysis on Alzheimer’s disease market
Table 2.1  Prevalence of AD 2006-2050 In Three Geographical Regions
Table 3.1  Assessment Scale for Defining Magnitude of AD
Table 3.1  contn’d Assessment Scale for defining magnitude of AD
Table 3.2  Summary of AD drugs clinical data
Table 3.3  SSRIs Considered in Managing Depression in AD
Table 3.4  Atypical antipsychotic agents considered in managing depression in AD
Table 3.5  Typical antipsychotic agents considered in managing depression in AD
Table 3.6  Anxiolytic Drugs Benzodiazepines Considered in Managing Depression in AD
Table 3.7  Mood-Stabilizing (anti-agitation) Drugs Considered in Managing Depression in AD
Table 5.1  The Global AD Market, 2004-2006
Table 5.2  Sales for AD Therapies in the US, 2003-2006
Table 5.3  US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.4 J apan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.5  Sales Revenues of AD Agents in France, 2003-2006
Table 5.6  France AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.7  Sales Revenues for AD Therapies in Germany, 2003-2006
Table 5.8  Germany AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.9  Sales Revenues for AD Therapies in the UK, 2003-2006
Table 5.10  UK  AD sales revenue forecast ($m), 2007-2012,2017 & 2022
Table 5.11  Italy’s Sales Revenues for AD Therapies, 2003-2006
Table 5.12  Italy AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Table 5.13  Spain Sales Revenues for AD Therapies, 2003-2006
Table 5.14  Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 6.1  Summary of Aricepts Approved indications for AD
Table 6.2  Present Aricept Extra indications in Major Markets
Table 6.3  Patent Expiration on leading AD products in Major Markets
Table 7.1  Alzheimer’s disease phase III Pipeline
Table 7.2  Alzheimer’s disease phase II Pipeline
Table 7.3  Alzheimer’s disease phase I Pipeline

List of Charts
Chart 1.1. Demographics of Alzheimer’s Disease Across Major Markets, 2006
Chart 1.2.  Aricept Total Sales Revenue Across Seven Major Markets, 2006
Chart 1.3.  Memantine Total Sales Revenue Across Six Major Markets, 2006
Chart 1.4.  Razadyne (previously Reminyl) Total Sales Revenue Across Six Major Markets, 2006
Chart 1.5.  Exelon Total Sales Revenue Across Six Major Markets, 2006
Chart 2.1.  Current and Projected Global Prevalence of Alzheimer’s Disease
Chart 2.2  Global Cost of AD During 2003-2005 ($bn)
Chart 5.1  The Global Sales ($m) of AD drugs, 2004-2006
Chart 5.2  The Global Market Share for Leading AD Drugs, 2006
Chart 5.3  Sales for AD Therapies in the US, 2003-2006
Chart 5.4  Market Share for AD agents in the US, 2006
Chart 5.5  US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.6  Aricept Sales Revenue,2003-2006
Chart 5.7  Japan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.8  Sale Revenues of AD Agents in France, 2003-2006
Chart 5.9  Market Share for AD Agents in France,2006
Chart 5.10  France AD Sales revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.11  Sales Revenues for AD Therapies in Germany, 2003-2006
Chart 5.12  Market Share for AD Agents in Germany,2006
Chart 5.13  Germany AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Chart 5.14  Sales Revenues for AD Therapies in the UK, 2003-2006
Chart 5.15  Market Share for AD Agents in the UK, 2006
Chart 5.16  UK AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Chart 5.17  Sales Revenues for AD Therapies in Italy, 2003-2006
Chart 5.18  Market Share for AD Agents in Italy,2006
Chart 5.19  Italy AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.20 Market Share for AD Agents in Spain, 2006
Chart 5.21  Market Share for AD Agents in Spain, 2006
Chart 5.22  Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022

Companies Listed

Abbott
Acambis
Accera
Aeolus
Affiris
Allon Therapeutics
Antigenics
AstraZeneca
Athenagen
Avera
Barr Pharmaceuticals
Bayer
BTG
CAD
Cell Genesys
Ceregene
Chiesi
CoMentis
Cortex
Cytos
Dae Wong
Daiichi Sankyo
Debiopharm
DebioPharma
Ebewe's
Eisai
Elan
Eli Lilly
Encore
Enkam
Epix Pharma
Evotec
First Horizon
Florida University
Forest 
GelTex
Genzyme
Helicon  Inflazyme
Hunter-Fleming
Inflazyme
Intellect Neuroscience
J&J
Janssen
Loyola Medical School
Lundbeck
Martek
Memory
Merck Serono
Merz
Migenix
Myriad
Neurochem
Neuro-Hitech
Neuropharma
Newron 
New York University
NicOx
Nippon Kayaku
Novartis
Nymox
Ono
Otsuka
Pfizer
Pharmexa
Pierre Fabre
Prana Technology
Procter and Gamble
Progenics
Roche 
Sagittarius
Sanofi Pasteur
Sanofi-Aventis
Shanghai Institute
Shire
Sloan Kettering
Synaptech
Taiho
Teva
The Stanley Medical
Torrey Pines Therapeutics
Toyama
Transition
UCB
UK- National Institute of Clinical Excellence (NICE)
University of Califonia
University of South Alabama
US Department of Health
Vasogen
Vernalis
Wyeth

2012 Copyright © visiongain. All rights reserved. BSG House, 226-236 City Road, London, EC1V 2QY, United Kingdom Web Design London